BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 11,937,882 shares of Editas Medicine, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported ownership of 11,937,882 shares of Editas Medicine common stock, representing 7.8% of the class.
  • Sole voting power: BlackRock reported sole voting power over 11,732,765 shares.
  • Sole dispositive power: BlackRock reported sole dispositive power over 11,937,882 shares.
  • No shared voting or dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Triggering event date: The date of event requiring the filing is listed as September 30, 2026.
  • Filer classification: BlackRock is identified as a parent holding company (type "HC"), incorporated in Delaware, with principal offices at 50 Hudson Yards, New York, NY 10001.

BlackRock's Schedule 13G Disclosure of Editas Medicine Holdings

According to the filing, BlackRock, Inc. submitted a Schedule 13G to report beneficial ownership of common stock of Editas Medicine, Inc. (issuer address: 11 Hurley St., Cambridge, MA 02141; CUSIP 28106W103). The statement reflects securities beneficially owned, or deemed to be beneficially owned, by certain business units of BlackRock, Inc. and its subsidiaries and affiliates, described in the filing as the "Reporting Business Units," in accordance with SEC Release No. 34-39538 (January 12, 1998).

The filing discloses that BlackRock holds an aggregate of 11,937,882 shares, equaling 7.8% of the outstanding class. Of those shares, 11,732,765 are subject to sole voting power, while the full 11,937,882 are subject to sole dispositive power. The filing notes that the schedule "does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units" under the referenced release.

Regarding Item 6, the filing states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Editas Medicine, Inc." and that "no one person's interest in the common stock of Editas Medicine, Inc. is more than five percent of the total outstanding common shares." The filing was signed by Spencer Fleming, Managing Director of BlackRock, Inc., on October 27, 2026. Subsidiary identification is provided in Exhibit 99 attached to the filing.

What Was Disclosed

BlackRock, Inc. filed a Schedule 13G reporting beneficial ownership of 11,937,882 shares of Editas Medicine, Inc. common stock, equal to 7.8% of the class, as of September 30, 2026, with no shared voting or dispositive power reported.